Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
[EN] SPIROCYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A<br/>[FR] DÉRIVÉS DE SPIROCYCLOPROPYLAMINE UTILES EN TANT QU'INHIBITEURS D'HISTONE DÉMÉTHYLASES KDM1A
申请人:IEO - ST EUROPEO DI ONCOLOGIA S R L
公开号:WO2017109061A1
公开(公告)日:2017-06-29
The present invention relates to provided spirocyclopropylamine compounds, endowed with a potent KDM1A (LSD1) inhibitory activity, wherein X, R, and R1 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy.